Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sage Therapeutic Com
(NQ:
SAGE
)
5.170
+0.320 (+6.60%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sage Therapeutic Com
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
November 22, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
November 14, 2022
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Retirement
Exposures
Pension
Product Safety
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
November 09, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate
October 17, 2022
Via
Benzinga
Sage Therapeutics: Q2 Earnings Insights
August 02, 2022
Sage Therapeutics (NASDAQ:SAGE) reported its Q2 earnings results on Tuesday, August 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
November 08, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Upgrades
Via
Benzinga
Where Sage Therapeutics Stands With Analysts
July 11, 2022
Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:
Via
Benzinga
8 Analysts Have This to Say About Sage Therapeutics
May 24, 2022
Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:
Via
Benzinga
Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer
November 01, 2022
From
Sage Therapeutics
Via
Business Wire
Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
October 25, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
October 17, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Mental Health Claims up 75% Since 2019
September 23, 2022
Canadian health insurers processed nearly $600 million in mental health service claims in 2021, up 75% from 2019 as more Canadians tapped into their mental health benefits. According to the Canadian...
Via
PressReach
Mental Health Claims up 75% Since 2019
September 23, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 23, 2022 – Canadian health insurers processed nearly $600 million in mental health service claims in 2021, up 75%...
Via
FinancialNewsMedia
Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
September 19, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Stock Scores Relative Strength Rating Upgrade
September 09, 2022
On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91.
Via
Investor's Business Daily
Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 02, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help
August 11, 2022
Today's depression drugs don't fit many patients' needs. Biotech companies may change that.
Via
Investor's Business Daily
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
August 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
August 02, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at Upcoming August Investor Conferences
August 01, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
July 19, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
June 29, 2022
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the...
Via
FinancialNewsMedia
Earnings Scheduled For August 2, 2022
August 02, 2022
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
Via
Benzinga
Sage Therapeutics to Present at Upcoming June Investor Conferences
June 02, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics And Biogen Tackle Depression — And Their Stocks Do The Same
June 01, 2022
Sage and Biogen say their MDD drug met every goal in a study of postpartum women.
Via
Investor's Business Daily
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
June 01, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Analyst Ratings for Sage Therapeutics
May 04, 2022
Over the past 3 months, 7 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding...
Via
Benzinga
Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
May 04, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.